Pyruvate, a key intermediate in glucose metabolism, was explored as a potential treatment in models of experimental stroke and inflammation. Pyruvate was administered to rodents after the onset of middle cerebral artery occlusion (MCAO). Since the extent of inflammation is often proportional to the size of the infarct, we also studied a group of animals given lipopolysaccharide (LPS) to cause brain inflammation without cell death. Following MCAO, pyruvate did not affect physiological parameters but significantly reduced infarct volume, improved behavioral tests and reduced numbers of neutrophils, microglial and NFκB activation. Animals given LPS showed increased microglial and NFκB activation which was almost completely abolished by pyruvate. Lactate, a major metabolite of pyruvate, was increased after pyruvate administration. However, administration of lactate itself did not have any anti-inflammatory effects. Pyruvate protects against ischemia possibly by blocking inflammation, but lactate itself does not appear to explain pyruvate's anti-inflammatory properties.
Introduction
Pyruvate, a final metabolite in glycolysis, has recently been shown to have salutary effects in brain ischemia (Lee et al. 2001; Yi et al. 2007; Yu et al. 2005 ). The precise mechanism of pyruvate's protective effect is unclear, but has been correlated to a reduction in microglial activation and the suppression of pro-inflammatory cytokines following focal cerebral ischemia. In related models of cardiac ischemia, pyruvate was also shown to have both cardioprotective and anti-oxidant properties (Woo et al. 2004 ). At the in vitro level, ethyl pyruvate was found to inhibit nuclear factor-kappa B (NFκB) activation in both cultured microglia (Kim et al. 2005 ) and RAW 264.7 cells (Han et al. 2005; Ulloa et al. 2002 ) through a modification of its p65 subunit. In models of lethal sepsis, ethyl pyruvate also reduced mortality and reduced circulating levels of HMBG1 (Ulloa et al. 2002) . Post ischemic inflammation, including activation of NFκB and inhibition of downstream immune mediators, has been established to contribute to ischemic progression (Wang et al. 2007 ). Thus, this anti-inflammatory property of ethyl pyruvate may be an important factor in its protective effect.
However, the ethyl group of ethyl pyruvate may itself have pharmacological actions which could have influenced prior observations. Whether pyruvate itself, an endogenous metabolic intermediate, also has anti-inflammatory effects is less clear. In order to study pyruvate in its more endogenous state, we study similar properties in sodium pyruvate. Further, whether sodium pyruvate has similar protective and anti-inflammatory properties is less clear, and the existing literature is conflicting (Gonzalez-Falcon et al. 2003; Kim et al. 2005; Lee et al. 2001) . We explore here whether sodium pyruvate protects against experimental stroke, and whether it does so via an anti-inflammatory mechanism using a model of brain inflammation that does not cause brain cell death. Since pyruvate can be rapidly metabolized to lactate, we also explored whether any anti-inflammatory effect of pyruvate may be mediated through this metabolite.
Materials and methods

Stroke model
All experiments were performed following an institutionally approved protocol in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Measures were taken, in accordance with the above guidelines to minimize pain and discomfort. Male Sprague-Dawley rats (Charles River) weighing between 270-300 g were anesthetized using isoflurane with a face mask and maintained with 1.5% isoflurane in 150 ml/min oxygen and 850 ml/min air. Rectal temperature and other physiological parameters were recorded every 15 min and maintained in the normal Neurobiology of Disease 36 (2009) 223-231 
